Legend Biotech Corporation (LEGN) Stock Analysis
Healthcare · Biotechnology
Sell if holding. Engine safety override at $26.94: Quality below floor (2.0 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.6/10 and A.R:R 5.7:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 23%; Below-average business quality; Negative price momentum.
Legend Biotech Corporation, through its subsidiaries, operates as a biopharmaceutical company that discovers, develops, manufactures, and commercializes novel cell therapies for oncology and other indications in the United States, China, and Europe. Its lead product candidate is... Read more
Sell if holding. Engine safety override at $26.94: Quality below floor (2.0 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.6/10 and A.R:R 5.7:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 23%; Below-average business quality; Negative price momentum. Chart setup: No recognized chart pattern (not a breakout, bounce, continuation, recovery, falling knife, or range) — technicals mixed. Score 5.6/10, moderate confidence.
Passes 8/10 gates (favorable risk/reward ratio, clean insider activity, no SEC red flags, news boost analyst 0.60, news boost analyst cluster(3), earnings proximity 83d clear, semi cycle peak clear, materials cycle peak clear). Fails on weak momentum and death cross (50MA < 200MA). Suitability: moderate.
Recent Developments — Legend Biotech Corporation
Latest news
- HC Wainwright & Co. Reiterates Buy on Legend Biotech, Maintains $50 Price Target — benzinga May 18, 2026 positive
- These Analysts Revise Their Forecasts On Legend Biotech After Q1 Results — benzinga May 13, 2026 positive
- TD Cowen Maintains Hold on Legend Biotech, Raises Price Target to $29 — benzinga May 13, 2026 positive
- Morgan Stanley Maintains Overweight on Legend Biotech, Lowers Price Target to $48 — benzinga May 13, 2026 positive
- RBC Capital Maintains Outperform on Legend Biotech, Raises Price Target to $64 — benzinga May 13, 2026 positive
Generated 2026-05-20T21:06:21Z.
Thesis
Key Metrics
Quality Signals
Options Flow
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer
Rating Breakdown
4 floor-breakers·1 ceiling hit
Clinical-stage biotech: losses expected pre-commercialisation. Quality floor doesn't distinguish R&D investment from operational decay — components above tell the real story.static
Momentum below the gate floor. Component breakdown shows what dragged the score down.static
Technicals below the gate floor. Component breakdown shows what dragged the score down.static
No near-term catalyst priced in. Thesis progression will come from fundamentals grinding, not event reaction.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $26.94: Quality below floor (2.0 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.6/10 and A.R:R 5.7:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 23%; Below-average business quality; Negative price momentum. Chart setup: No recognized chart pattern (not a breakout, bounce, continuation, recovery, falling knife, or range) — technicals mixed. Prior stop was $25.05. Score 5.6/10, moderate confidence.
Take-profit target: $49.86 (+85.1% upside). Prior stop was $25.05. Stop-loss: $25.05.
Quality below floor (2.0 < 4.0).
Legend Biotech Corporation trades at a P/E of N/A (forward 20.2). TrendMatrix value score: 8.0/10. Verdict: Sell.
24 analysts cover LEGN with a consensus score of 4.2/5. Average price target: $55.
What does Legend Biotech Corporation do?Legend Biotech Corporation, through its subsidiaries, operates as a biopharmaceutical company that discovers, develops,...
Legend Biotech Corporation, through its subsidiaries, operates as a biopharmaceutical company that discovers, develops, manufactures, and commercializes novel cell therapies for oncology and other indications in the United States, China, and Europe. Its lead product candidate is ciltacabtagene autoleucel, or cilta-cel, which is a chimeric antigen receptor (CAR-T) therapy for the treatment of multiple myeloma (MM). The company also has a portfolio of earlier-stage autologous CAR-T product candidates targeting various cancers, including acute lymphoblastic leukemia, gastric cancer, esophageal cancer, pancreatic cancer, colorectal cancer, small cell lung cancer, and non-small cell lung cancer. In addition, it develops allogeneic gamma delta CAR-T and allogeneic CAR-NK product candidates targeting B-cell maturation antigen (BCMA) for MM, which are in investigator-initiated Phase 1 clinical trials in China. The company has a collaboration and license agreement with Janssen Biotech, Inc. for the development and commercialization of cilta-cel, as well as a license agreement with Novartis Pharma AG for the development, manufacture, and commercialization of CAR-T cell therapies targeting delta-like ligand protein 3. Legend Biotech Corporation was founded in 2014 and is headquartered in Somerset, New Jersey.